Bottom line
Is DLHCX a good fund? The bottom line
DLHCX is the Class C share class of Nomura Healthcare Fund, an actively managed health care sector mutual fund from Voya.
It charges 1.96% — about $196 a year on every $10,000 invested, more expensive than 93% of health care sector funds we track.
It returned +20.2% over one year, +6.7% a year over five years, +9.3% a year over ten (as of Dec 31, 2025, per its prospectus).
With $750 million in net assets and 108 holdings, its largest position is Ucb Sa (5.2%) and the top 10 make up 38.9% of the portfolio.
What stands out
- 5-year return beat 81% of category peers
- No front-end sales load
What to watch
- Expensive for its category (1.96%)
- 12b-1 marketing fee of 1% a year
Updated Nov 19, 2026
What DLHCX invests in
Nomura Healthcare Fund seeks maximum long-term capital growth through capital appreciation.
Under normal circumstances, Nomura Healthcare Fund ?will invest at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in the equity securities of healthcare companies (80% policy). For purposes of the Funds 80% policy, healthcare companies include those companies that develop, produce, or distribute products or services related to the healthcare or medical industries and derive a substantial portion of their sales from products and services in the healthcare industry. These products and services include, but are not limited to, pharmaceutical companies, biotechnology companies, medical device and supply companies, managed care companies, and healthcare information and service providers. The Fund invests in US and non-US companies across all market capitalizations. The Fund may invest up to 50% of its total assets in non-US companies. The Fund may…
From the fund's prospectus (filed Jul 29, 2026).
DLHCX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| DLHCX | +20.2% | +6.7% | +9.3% |
| Health Care Sector median | +14.5% | +4.2% | +7.9% |
Source: Fund prospectus, as of Dec 31, 2025
What DLHCX costs
On a $10,000 investment, DLHCX's 1.96% expense ratio costs about $196 a year. The prospectus estimates $2,334 in total costs over 10 years (assuming 5% annual returns). The median health care sector fund charges 0.96%.
DLHCX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Ucb Sa UCB | 5.19% |
| 2 | Abbvie Inc ABBV | 4.19% |
| 3 | Eli Lilly & Company LLY | 4.16% |
| 4 | Regeneron Pharmaceuticals Inc REGN | 3.91% |
| 5 | Unitedhealth Group Inc UNH | 3.88% |
| 6 | Pfizer Inc PFE | 3.84% |
| 7 | Merck & Company Inc MRK | 3.68% |
| 8 | Gilead Sciences Inc GILD | 3.54% |
| 9 | Astrazeneca Plc AZN | 3.27% |
| 10 | Elevance Health Inc ELV | 3.25% |
Source: SEC Form N-PORT, period ended Jun 30, 2026
The top 10 make up 38.9% of the fund. See all top 25 holdings and asset mix →